Table 3.
Association of ELN2017 genetic-risk group and the presence of MRD in patients with AML before allogeneic HSCT
| Characteristics | All (N = 234) | ELN2017 favorable (n = 93) | ELN2017 intermediate (n = 30) | ELN2017 adverse (n = 111) | P* |
|---|---|---|---|---|---|
| BAALC MRD at HSCT, n (%) | .99 | ||||
| Negative | 49 (68.1) | 21 (67.7) | 8 (66.7) | 20 (69.0) | |
| Positive | 23 (31.9) | 10 (32.3) | 4 (33.3) | 9 (31.0) | |
| MN1 MRD at HSCT, n (%) | .99 | ||||
| Negative | 50 (70.4) | 22 (71.0) | 8 (66.7) | 20 (71.4) | |
| Positive | 21 (29.6) | 9 (29.0) | 4 (33.3) | 8 (28.6) | |
| Mutated NPM1 MRD at HSCT, n (%) | .55 | ||||
| Negative | 32 (71.1) | 29 (69.0) | 3 (100.0) | — | |
| Positive | 13 (28.9) | 13 (31.0) | 0 (0.0) | — |
*
Fisher’s exact test, comparing the 3 ELN2017 genetic-risk groups.